Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Virpax And MedPharm Advance Diclofenac Spray

Transdermal Osteoarthritis Treatment To Be Submitted Via 505(b)(2) Pathway In US

Executive Summary

Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.

You may also be interested in...



North Carolina Facility Doubles MedPharm Footprint For Developing Topicals, Transdermals

UK firm opens site in North Carolina’s Research Triangle Park to expand its contract formulation development services for OTC and Rx topical and transdermal products. It has supported projects with six of the eight leading OTC companies.

Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’

Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.

Amzell Sees Benefit From High-Strength Topical Diclofenac

Amzell has revealed trial results indicating that its diclofenac 3.06% gel formulation is effective for treating knee osteoarthritis symptoms.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel